Spondylolysis
disease diseaseOn this page
Also known as spondylolysis (disease)
Summary
Spondylolysis (MONDO:0005541) is a disease with 1 GWAS associations across 1 studies and 11 clinical trials. Top therapeutic interventions include bupivacaine. A subtype of disease of bone structure — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | spondylolysis |
| Mondo ID | MONDO:0005541 |
| EFO | EFO:0005649 |
| MeSH | D013169 |
| DOID | DOID:2300 |
| ICD-10-CM | M43.0 |
| ICD-11 | 790009325 |
| NCIT | C35034 |
| SNOMED CT | 240221008 |
| UMLS | C0038018 |
| MedGen | 21294 |
| Anatomy (UBERON) | UBERON:0036266 |
| Is cancer (heuristic) | no |
Also known as: spondylolysis · spondylolysis (disease)
Data availability: 1 GWAS association (1 study) · 1 HPO phenotype.
Disease family
This is a subtype of disease of bone structure. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › disease of bone structure › spondylolysis
Related subtypes (4): spondylosis, scoliosis, spinal stenosis, spondylolisthesis
Genetics & variants
GWAS landscape
1 GWAS associations across 1 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs56038849 | 1e-07 | IGKC | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90651843 | Liu TY | 2025 | 700 | 231,760 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 1 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 0 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| 3_prime_UTR_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs56038849 | 2 | 88857162 | C>A,T | 0.05 | 3_prime_UTR_variant | IGKC | 1e-07 | Tier 2: splice/UTR |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03514277 | PHASE4 | TERMINATED | A Prospective Study to Compare Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Pain Relief |
| NCT02854904 | PHASE2/PHASE3 | UNKNOWN | Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion |
| NCT06666608 | Not specified | RECRUITING | Bone Stimulator for Spondylolysis |
| NCT00585923 | Not specified | TERMINATED | Slotted Hole Versus Fixed Hole C-Tek |
| NCT01711203 | Not specified | COMPLETED | The Addition of a Pilates Program for Short-Term Improvements in Patients With Spondylolysis or Spondylolisthesis |
| NCT02070484 | Not specified | TERMINATED | Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease |
| NCT02129374 | Not specified | COMPLETED | Direct Repair Surgery for Spondylolysis of Lumbar in Young Population |
| NCT02332200 | Not specified | COMPLETED | Rest Before Physical Therapy in Adolescents With Active Spondylolysis and Spondylolisthesis |
| NCT02861456 | Not specified | COMPLETED | Feasibility of Using Functional Progression to Guide the Treatment of Adolescent Low Back Pain |
| NCT04814979 | Not specified | COMPLETED | Effects of Low-intensity Pulsed Ultrasound on Pain and Functional Disability in Patients With Lumbar Spondylolysis |
| NCT06284967 | Not specified | UNKNOWN | Association Of Serum Vitamin D Level With Isthmic Spondylolysis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BUPIVACAINE | 4 | 1 |
Related Atlas pages
- Drugs: Bupivacaine